Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Peptide
VEGF-stimulated human umbilical vein endothelial cells (HUVECs)
Tissue
N/A nM (reported value)
In vivo mice.
N/A°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
See also PVV peptide , which also results in tumor growth suppression.
See also DRW peptide , which contains the same WRP epitope resulting in suppression of tumor growth.
VEGF-stimulated HUVECs (ID# 231)
See also DRW peptide , which contains the same WRP epitope resulting in suppression of tumor growth.
NH2AlaSerSerSerTyrProLeuIleHisTrpArgProTrpAlaArgCOOCOOH
15
2017.31 g/mole
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Asai et al. "Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels." FEBS Letters, 510(2002): 206-210.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.